Alex Pasteur joined F-Prime in 2012 and is a Partner based in London.  Alex focuses on investments in therapeutics and the convergence of life sciences with data science.  Alex serves on the boards of ARTBIO, Nodthera, Tenpoint Therapeutics, Pulmocide, Peptone, Oviva, Genomics Ltd, Owkin and Shift Bioscience.  He is an observer on the board of Castor.

Alex previously served on the boards of Orchard Therapeutics (acquired by Kyowa Kirin), Acacia Pharma (acquired by Eagle Pharmaceuticals), Arvelle Therapeutics (acquired by Angelini Pharma) and as observer for Adaptimmune Therapeutics (NASDAQ: ADAP).

Alex has worked in healthcare investing since 2001.  Prior to joining F-Prime, Alex worked at MVM Life Science Partners LLP in the USA and Europe.  Alex holds a M.A. in Natural Sciences from Cambridge University and a Ph.D. in Chemistry from Cambridge University.